PHAT

4.6608.27%
SL

Steven L. Basta

CEO, President & Director

Mr. Steven L. Basta, M.B.A., also known as Steve, serves as Chief Executive Officer, President and Director at Phathom Pharmaceuticals, Inc. from April 1, 2025. He is Director of DermBiont, Inc. He served as Chief Executive Officer of SaNOtize Research and Development Corp. from September 2023 until March 2025. He had been Independent Chairman of the Board of Viveve Medical, Inc. since January 16, 2019 until March 2023. He served as Chief Executive Officer at Mahana Therapeutics, Inc. since December 2020 until 2022. Mr. Basta has been Director of Viveve Medical Inc. since September 13, 2018. Mr. Basta is a Business Advisor at Spindletop Capital. Previously, he served as a Member of Executive Council and Venture Partner at the firm. Mr. Basta served as the Chief Executive Officer of AlterG, Inc. from October 2011 to August 2015. Before joining AlterG, he led several emerging biopharmaceutical and medical device companies. He served as the Chief Executive Officer of Merz Aesthetics, Inc. from November 2002 to September 2011 and served as its President from December 2000 to June 2007. From November 2002 to February 2010, he served as Chief Executive Officer of BioForm Medical, Inc. He served as Vice President of Finance and Business Development at Curis, Inc. He joined Merz Aesthetics, Inc. in December 2000. He served as the President and Chief Executive Officer of Gliatech Inc. since December 2000. Prior to joining Gliatech Inc., he served as Treasurer of Creative Biomolecules Inc. He served as Vice President of Finance and Business Development and Chief Financial Officer of Creative BioMolecules, Inc. from January 1999 to August 2000 and served as its Vice President of Corporate Development & Investor Relations from February 1997 to January 1999. He was associated with Jundt Associates from June 1996 to December 1996. From September 1990 to June 1996, he held several positions with The Immune Response Corporation, including an Executive Director of Product Development from 1994 to 1996, Program Director for an HIV research joint venture from 1992 to 1993 and Director of Investor Relations & Market Development from 1991 to 1992. He served as an Associate with Dillon, Read & Co, Inc. from 1988 to 1990, where he began his career. He served as a Director of RF Surgical Systems, Inc. from December 2013 to August 2015. He served as a Director of Carbylan Therapeutics, Inc., since September 2009 to November 2016. He served as a Director of Merz Aesthetics, Inc. since November 2002, AlterG, Inc. from November 2002 to September 7, 2015 and Gliatech Inc. since February 2001. He served as Director of KalVista Pharmaceuticals, Inc until November 22, 2016. Mr. Basta received a B.A. in Bio Medical Engineering from The Johns Hopkins University and an MBA from the Kellogg Graduate School of Business at Northwestern University. He served as Director of VYNE Therapeutics Inc. (formerly known as Menlo Therapeutics Inc.). since September 2015 and served as its the Chief Executive Officer and President since September 2015 until March 2020.

Positions